| Arthritis, Psoriatic

Bimzelx vs Renflexis

Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.

Deep comparison between: Bimzelx vs Renflexis with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRenflexis has a higher rate of injection site reactions vs Bimzelx based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Renflexis but not Bimzelx, including UnitedHealthcare

Category

Bimzelx

Renflexis

At A Glance

RouteSC injection

FrequencyEvery 4-8 weeks

ClassIL-17A and F antagonist

RouteIV infusion

FrequencyEvery 6-8 weeks

ClassTNF-alpha antagonist

Indications

Psoriasis vulgaris
Arthritis, Psoriatic
Non-Radiographic Axial Spondyloarthritis
Ankylosing spondylitis
Hidradenitis Suppurativa

Crohn Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing spondylitis
Arthritis, Psoriatic
Psoriasis vulgaris

Dosing

Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.

Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.

Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.

Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks; pediatric patients >= 6 years with Crohn Disease or Ulcerative Colitis receive the same regimen.

Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete response.

Ankylosing spondylitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 6 weeks.

Contraindications

—

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of RENFLEXIS, or any murine proteins

Drug Interactions

833View drug interactions

1225View drug interactions

Adverse Reactions

Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection

Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease

Postmarketing Conjunctivitis, esophageal candidiasis

Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain

Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis), hepatotoxicity, malignancies, severe infusion reactions

Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction

Pharmacology

Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.

TNF-alpha antagonist; infliximab-abda is a chimeric IgG1kappa monoclonal antibody that neutralizes TNF-alpha by binding with high affinity to soluble and transmembrane forms of TNF-alpha, inhibiting receptor binding and suppressing downstream pro-inflammatory activity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Bimzelx